1. Home
  2. AMTB vs PHAT Comparison

AMTB vs PHAT Comparison

Compare AMTB & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amerant Bancorp Inc.

AMTB

Amerant Bancorp Inc.

HOLD

Current Price

$20.07

Market Cap

776.2M

Sector

Finance

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$17.50

Market Cap

942.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMTB
PHAT
Founded
1979
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
776.2M
942.6M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
AMTB
PHAT
Price
$20.07
$17.50
Analyst Decision
Buy
Strong Buy
Analyst Count
4
6
Target Price
$21.75
$17.33
AVG Volume (30 Days)
226.1K
874.8K
Earning Date
01-21-2026
10-30-2025
Dividend Yield
1.78%
N/A
EPS Growth
N/A
N/A
EPS
1.59
N/A
Revenue
$388,504,000.00
$147,190,000.00
Revenue This Year
$61.42
$220.37
Revenue Next Year
$2.10
$83.14
P/E Ratio
$12.72
N/A
Revenue Growth
51.98
460.30
52 Week Low
$15.62
$2.21
52 Week High
$24.40
$18.31

Technical Indicators

Market Signals
Indicator
AMTB
PHAT
Relative Strength Index (RSI) 58.41 66.74
Support Level $20.09 $16.77
Resistance Level $20.50 $18.31
Average True Range (ATR) 0.48 0.88
MACD -0.07 0.26
Stochastic Oscillator 45.61 79.95

Price Performance

Historical Comparison
AMTB
PHAT

About AMTB Amerant Bancorp Inc.

Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: